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Introduction 
Xanthomonas maltophilia is a recognized although unusual 
pathogen in patients with cystic fibrosis (CF). The present 
report describes the case of an adult with CF from whose 
sputum X maltophilia was isolated repeatedly, and despite 
intensive intravenous (i.v.) antibiotic therapy, his condition 
deteriorated until high-dose oral co-trimoxazole was intro- 
duced. For the next 12 months, he remained well on 
intermittent high-dose co-trimoxazole and daily nebulized 
colistin. As his condition had stabilized, a trial period off 
co-trimoxazole was embarked upon, and 1 month later, he 
deteriorated and was re-admitted for i.v. antibiotic therapy. 
He is now back on regular thrice-weekly high-dose 
co-trimoxazole and nebulized colistin, and has remained 
well for a further 6 months. 
Case Report 
A 25-year-old garage mechanic was diagnosed as having 
CF at the age of 10 years when he presented with a 
persistent cough, failure to gain weight and steatorrhea. 
Over the next 3 years, he was admitted three times with 
meconium ileus equivalent and remained well otherwise, 
performing daily physiotherapy. At 15 years of age, 
Staphylcoccus aureus was cultured from the sputum, and 
the following year, he was admitted for the first time for 
treatment of an infective pulmonary exacerbation. Five 
years later, having been admitted on three further occasions 
for intravenous (i.v.) antibiotics, Pseudomonas aeruginosa 
was isolated from the sputum. At this stage, pulmonary 
function was fairly well maintained with a forced expiratory 
volume in 1 s (FEV,) of 2.7 1 (65% predicted normal range 
(1)) and a forced vital capacity (FVC) of 3.8 1 (76% 
predicted). Eighteen months later, he developed asthma and 
started inhaled cortico-steroids. 
Table 1 illustrates his subsequent progress. At the age of 
24 years, X maltophilia was isolated from the sputum for 
the first time. Over the next 18 months, the number of 
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exacerbations requiring hospital admission increased to 
eight. Despite intensive therapy with i.v. and nebulized 
antibiotics, and continuous oral and inhaled corticosteroids 
for associated bronchospasm, his lung function deterio- 
rated markedly (FEV, 20% predicted) and he was no longer 
able to continue working. During this time, X maltophilia, 
which was isolated consistently from the sputum, remained 
resistant to all conventional agents, save colistin. Suscepti- 
bility testing was extended to co-trimoxazole to which the 
pathogen was found to be susceptible. Following high-dose 
co-trimoxazole (1.44 g b.i.d.) and an increase in the dose of 
nebulized colistin (from 1 to 2 mega units b.i.d.), his clinical 
condition improved markedly (Table 1). Fourteen days 
later, he was discharged home taking high-dose 
co-trimoxazole for a further week. In order to try and 
maintain his lung function, a regimen of daily nebulized 
colistin (one mega unit b.i.d.) and co-trimoxazole 
(1.44 g b.i.d.) thrice weekly was instituted. This therapy was 
continued for the following 12 months and as his condition 
had stabilized (Table l), a trial period off co-trimoxazole 
was embarked upon, although colistin was continued. 
X maltophilia continued to be isolated consistently from 
the sputum. 
One month later, his clinical condition deteriorated. He 
was re-admitted for iv. antibiotics and was treated for 10 
days with iv. gentamicin (100 mg t.i.d.) and i.v. aztreonam 
(2 g t.i.d.). He is now back on regular thrice-weekly high- 
dose co-trimoxazole with daily nebulized colistin and has 
remained well for 6 months; indeed, for the last four 
months, X maltophilia has not been isolated from the 
sputum which has been cultured every 4-8 weeks. Chest 
radiographic appearances have not changed greatly over 
the past 2 years. 
Discussion 
X maltophilia is a recognized sputum pathogen in cystic 
fibrosis (2); it is not clear if its presence contributes to 
deterioration in lung function. A recent review of 23 CF 
children showed that acquisition of this organism was not 
associated with unexpected deterioration (3). Should, how- 
ever, X maltophilia contribute significantly to deteriorating 
lung function, the choice of effective therapy is limited 
in view of its inherent resistance to the majority of anti- 
microbial agents available (4,5). In vitro susceptibility of 
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TABLE 1. 
Age FEV, 
Year (years) (% predicted) 
FVC No. admissions per year Sputum 
(% predicted) for i.v. antibiotics pathogens Additional data 
1983 16 
1987 20 
1988 21 
1989 22 
1990 23 
1991 24 
1992 
25 
1992 
1993 26 
3.2 (91%) 4.2 (111%) 
3.0 (72%) 4.17 (83%) 
2.7 (65%) 3.8 (76%) 
2.3 (55%) 3.1 (62%) 
1.2 (29%) 1.9 (38%) 
1.5 (36%) 2.5 (50%) 
0.85 (20%) 1.25 (25%) 
1.8 (42%) 3.4 (66%) 
1.5 (34%) 3.1 (61%) 
S. aureus 
H. infuenzae Flucloxacillin started 
S. aureus 
P. aeruginosa 
P. aeruginosa 
S. aureus 
H. influenzae 
All above Oral and inhaled steroids 
started 
X. maltophilia Developed diabetes, 
nebulized antibiotics 
started 
X maltophilia Marked deterioration 
S. aureus FEV, reduced to 20% 
H. influenzae High-dose co-trimoxazole 
started 
X. maltophilia Regained stability 
S. aureus 
H. infuenzae 
X maltophilia to co-trimoxazole has been demonstrated and/or by controlling the effects of other infective agents, 
previously (6) and it is of interest that synergism of e.g. Pneumocystis carinii, which were not identified by 
aztreonam and clavulanic acid has also been described (5). routine microbiological screening tests. 
To the authors’ knowledge, this is the first report of 
successful clinical application of co-trimoxazole in CF 
pulmonary infection associated with X maltophilia. This 
agent has been effective both in the treatment of acute 
exacerbations associated with X. maltophilia and also in the 
maintenance of lung function for 18 months. Long-term 
therapy has been well tolerated and, indeed, its protracted 
use may have contributed to the eradication of this patho- 
gen. The intermittent time course using high-dose therapy 
was introduced in an attempt to achieve bactericidal effects 
whilst minimizing the development of resistance to 
co-trimoxazole. Sequential sputum cultures of X mal- 
tophilia from this patient have been of varying sensitivity to 
both trimethoprim and sulphamethoxazole, although it 
appears that in vivo activity has been maintained. It is of 
note that prolonged use of high-dose nebulized colistin was 
also well tolerated and in vitro sensitivity to this agent 
was retained. The possibility of nebulized co-trimoxazole 
may be considered in the future for the treatment of 
X maltophilia infection in CF. However, it should be 
recognized that as X maltophilia was retained during 
periods of clinical stability despite concurrent co- 
trimoxazole therapy, this antibiotic may have been effective 
by reducing exo-enzyme expression by X. maltophilia 
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